Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IQV - IQVIA Holdings Inc


Close
251.55
0.760   0.302%

Share volume: 1,194,435
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$250.79
0.76
0.30%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
54%
Profitability 34%
Dept financing 48%
Liquidity 52%
Performance 74%
Company vs Stock growth
vs
Performance
5 Days
1.05%
1 Month
2.44%
3 Months
13.08%
6 Months
0.50%
1 Year
12.02%
2 Year
16.46%
Key data
Stock price
$251.55
P/E Ratio 
32.23
DAY RANGE
$246.85 - $252.27
EPS 
$7.71
52 WEEK RANGE
$167.42 - $261.73
52 WEEK CHANGE
$0.12
MARKET CAP 
45.858 B
YIELD 
N/A
SHARES OUTSTANDING 
182.300 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$725,201
AVERAGE 30 VOLUME 
$818,355
Company detail
CEO: Ari Bousbib
Region: US
Website: https://ir.iqvia.com/
Employees: 67,893
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

quintiles and imshealth have merged together to form the new quintilesims. each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. quintilesims has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. as a global leader in protecting individual patient privacy, quintilesims uses healthcare data to deliver critical, real-world disease and treatment insights. to learn more, visit www.quintilesims.com

Recent news